Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 62Gastrointestinal 7Gynecologic 4Genitourinary 4Thoracic 3Other solid neoplasm 3Tumor-Agnostic 2Endocrine 2CNS 2NET 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Lung Neoplasms 1

Interventions

Carboplatin 335Pemetrexed 276Cisplatin 228Paclitaxel 193pembrolizumab 178Erlotinib Hydrochloride 173Docetaxel 154Gemcitabine 126Nivolumab 112Bevacizumab 112Radiotherapy 84Etoposide 68durvalumab 62atezolizumab 59Ipilimumab 51Radiosurgery 49osimertinib 42130-nm albumin-bound paclitaxel 40Afatinib 39Gefitinib 38Cetuximab 38Albumin-Bound Paclitaxel 37Taxes 32Vinorelbine 29Radiation 29Topotecan 28Drug Therapy 25Crizotinib 23Platinum 21Dexamethasone 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × pertuzumab × Thoracic × Clear all
NCT02507375 2015-10-16

A Study of Pertuzumab With Erlotinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Hoffmann-La Roche

Phase 1 Completed
17 enrolled 15 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00063154 2015-07-07

Safety and Effect of Pertuzumab in Patients With Advanced Non-Small Cell Lung Cancer, Which Has Progressed After Prior Chemotherapy

Genentech, Inc.

Phase 2 Completed
51 enrolled 9 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00855894 2013-05-21

PENGUIN

Genentech, Inc.

Phase 2 Completed
41 enrolled 10 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡